Vitiligo on Black Skin: Treatment That Actually Works

Vitiligo is an autoimmune disease in which the immune system destroys melanocytes, the cells that make skin pigment, leaving smooth white or depigmented patches. It is not contagious, it is not caused by anything you ate, touched, or did, and it is not a sign of poor hygiene. It affects roughly the same share of people across racial groups, around 1% to 1.4% of adults in the United States, but on brown and black skin the contrast between pigmented and depigmented areas is stark, which is why the disease feels more visible and weighs heavier here.

In vitiligo, the immune system mistakenly attacks and kills melanocytes. Without those cells, the skin in that spot makes no pigment and turns white. The patches are usually smooth, not scaly or itchy, and they often show up first in places exposed to friction or sun: the hands, face, around the eyes and mouth, elbows, knees, and genitals. It can also turn patches of hair white. Nothing the person did causes it, and you cannot catch it from someone who has it. Those two facts matter, because the stigma around vitiligo, the staring, the questions, the false belief that it is a fungus or contagious, is often heavier than the medical disease itself.

Non-segmental vitiligo is by far the most common, roughly 85% to 90% of cases. It tends to appear symmetrically on both sides of the body, can spread over time, and is the type most clearly tied to autoimmune activity. Segmental vitiligo is the minority pattern. It appears on one side of the body in a band or segment, often starts younger, spreads quickly for about a year, then usually stops and stays stable. The distinction is not academic: it changes treatment. Stable segmental disease that has stopped spreading is the form most likely to be a candidate for surgical grafting, while non-segmental vitiligo is the form the newer creams and phototherapy target.

Vitiligo rarely travels alone. Because it is autoimmune, it raises the odds of other autoimmune conditions, and knowing that lets you catch them early. In a meta-analysis of US adults with vitiligo, the most common associated condition was thyroid disease, at a pooled prevalence near 14%, followed by psoriasis (about 5%), rheumatoid arthritis (about 3%), alopecia areata (about 3%), type 1 diabetes (about 2%), and pernicious anemia (about 2%). Thyroid disease is the standout, which is why a thyroid check (TSH, often with thyroid antibodies) is a reasonable thing to ask for after a vitiligo diagnosis. The more skin surface vitiligo covers, the higher the odds of these companions, so wider disease is a stronger reason to screen.

If thyroid screening turns up a problem, it often comes with its own skin and hair signals. Our guide to thyroid disease signs in the skin and hair of Black women covers what to watch for and which labs to ask about.

Vitiligo is not painful, but its psychological weight is well documented and is greater for people with darker skin, more body surface involved, or patches on the face and hands. In the global VALIANT study of 3,541 patients across 17 countries, 58.7% reported a diagnosed mental health condition, 28.8% reported diagnosed anxiety, and 24.5% reported diagnosed depression. More than half had moderate to severe depressive symptoms, and nearly half said vitiligo made them feel less confident or more self-conscious. A population study across Europe, Japan, and the US found that quality of life was worse for people with more extensive disease and for those with lesions on the head and hands. This is not vanity. It is a measurable burden, and it is a legitimate reason to treat, to seek therapy, or both.

Repigmentation is slow and uneven. The face and neck respond best. Hands, feet, and bony areas are stubborn and often respond least. Treatment can stop spread and bring color back, but it takes months, and results vary by where the patches sit. Here is what is actually on the table.

Topical corticosteroids and topical calcineurin inhibitors (tacrolimus, pimecrolimus) are long-standing first-line options for limited disease, with calcineurin inhibitors often preferred for the face and around the eyes because they avoid the skin-thinning that long-term steroids can cause. The bigger development is ruxolitinib cream 1.5% (Opzelura), a topical JAK inhibitor the FDA approved in July 2022 for non-segmental vitiligo in patients 12 and older. It is the first drug ever approved to repigment vitiligo rather than just slow it. In the phase 3 TRuE-V trials, about 30% of patients reached at least 75% improvement in facial pigmentation (F-VASI75) by week 24, and roughly half reached that mark by week 52. The face responds far better than the hands, and treatment often runs well beyond 24 weeks before the full benefit shows.

Narrowband UVB phototherapy (311 to 313 nm) is the workhorse for widespread non-segmental vitiligo, delivered in a clinic light box or sometimes a home unit, typically two to three times a week. For small, localized patches, the 308 nm excimer laser targets pigment loss spot by spot and can work faster on limited areas. Phototherapy is frequently combined with topical creams to push repigmentation further.

For vitiligo that has stayed stable, especially segmental disease that stopped spreading, surgical options such as skin grafting and melanocyte transplantation can move pigment-producing cells into white patches. Surgery is reserved for stable disease because grafting into actively spreading vitiligo tends to fail. Outside of medical treatment, cosmetic camouflage (color-matched concealers, self-tanners with dihydroxyacetone, medical tattooing for small stable spots) and daily, diligent sun protection both matter. Depigmented skin has no melanin shield, so it burns easily, and protecting the surrounding pigmented skin keeps the contrast from sharpening.

Itchy or scaly patches are not vitiligo, which is smooth and not inflamed. If your patches itch, flake, or thicken, the diagnosis may be something else; our guide to managing eczema on Black skin walks through how that condition reads on dark skin.

Vitiligo on dark skin is best managed by a dermatologist who treats skin of color regularly, because repigmentation patterns, contrast, and post-treatment pigment changes all read differently on brown and black skin. A clinician who knows that will set realistic expectations by body area and will not mistake your patches for a fungal infection or a cosmetic concern. You can find a Black dermatologist in our directory. Bring a timeline of when the patches appeared and whether they are spreading, photos if you have them, and a written ask for a thyroid screen.